Key and Other Secondary Outcomes at 28 Days
pulmonary embolism, bleeding, Thrombosis, peripheral artery disease, thrombotic, heart failure
PULMONARY EMBOLISM, THROMBOEMBOLIC EVENT, PERIPHERAL ARTERY DISEASE, MYOCARDIAL INFARCTION, CARDIOVASCULAR DISEASE, BLEEDING, DEEP VEIN THROMBOSIS, COMPARTMENT SYNDROME, THROMBOSIS, ISCHEMIC STROKE, CEREBROVASCULAR DISEASE, EVENTS, HEART FAILURE, HYPERTENSION, CORONARY ARTERY DISEASE
Data expressed as number (percentage).Odds ratio less than 1 corresponds to treatment benefit (eg, treatment is associated with fewer events).Adjusted for age, sex, enrollment epoch, cardiovascular disease (composite of hypertension, heart failure, coronary artery disease, peripheral artery disease, and cerebrovascular disease), sodium-glucose cotransporter 2 assignment, and baseline mechanical ventilation; study country and site are treated as nested random effects.Major thrombotic events include pulmonary embolism, myocardial infarction, ischemic stroke, and other arterial or venous thromboembolic events.Any thrombotic events include major thrombotic events and deep vein thrombosis.Major bleeding events are defined accordingly by the International Society on Thrombosis and Hemostasis: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a decrease in hemoglobin level of 2 g/dL or more (to convert to grams per liter, multiply by 10) or leading to transfusion of 2 or more units of whole blood or red cells.